Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1984-09-11
1986-09-02
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514376, 514398, 514409, 514913, A61K 3144, A61K 3142, A61K 3140, A61K 31415
Patent
active
046096639
ABSTRACT:
Method of treating glaucoma comprising the topical or systemic application of an aldose reductase inhibitor; compositions comprising such inhibitors are also disclosed.
REFERENCES:
patent: 3821383 (1974-06-01), Sestanj
patent: 4117230 (1978-09-01), Sarges
patent: 4130714 (1978-12-01), Sarges
patent: 4181728 (1980-01-01), Sarges et al.
patent: 4209630 (1980-06-01), Sarges
patent: 4226875 (1980-10-01), Schnur
patent: 4307108 (1981-12-01), Belletire et al.
patent: 4436745 (1984-03-01), York, Jr.
patent: 4438272 (1984-03-01), York, Jr.
patent: 4454154 (1984-06-01), Matier
patent: 4455317 (1984-06-01), Matier
patent: 4457939 (1984-07-01), Schnur
patent: 4503066 (1985-03-01), Brittain et al.
Textbook of Medicine, vol. II--1975--p. 1606--W. B. Saunders Co. --Philadelphia, Pa.
Chem. Abst. 90: 166024(u) (1979)--Koraszewsku et al.
U.S. patent application Ser. No. 532,168, York, Jr.
Clinical Ophthalmology, vol. 3, Chapter 54, pp. 1 and 15-17 (1984).
Clinical Ophthalmology, vol. 3, Chapter 55, pp. 13-14 (1984).
Clinical Glaucoma, Chapter 9, pp. 129-130 (1977).
Early Primary Open-Angle Glaucoma: Diagnosis and Management, pp. 180-183 (1979).
Alcon Laboratories Inc.
Arno James A.
Brown Gregg C.
Robinson Douglas W.
LandOfFree
Aldose reductase inhibitors useful in glaucoma therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aldose reductase inhibitors useful in glaucoma therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aldose reductase inhibitors useful in glaucoma therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1097813